JP2005501532A5 - - Google Patents

Download PDF

Info

Publication number
JP2005501532A5
JP2005501532A5 JP2003506300A JP2003506300A JP2005501532A5 JP 2005501532 A5 JP2005501532 A5 JP 2005501532A5 JP 2003506300 A JP2003506300 A JP 2003506300A JP 2003506300 A JP2003506300 A JP 2003506300A JP 2005501532 A5 JP2005501532 A5 JP 2005501532A5
Authority
JP
Japan
Prior art keywords
antigens
examples
derived
pathogens
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003506300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005501532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/017374 external-priority patent/WO2002102828A2/en
Publication of JP2005501532A publication Critical patent/JP2005501532A/ja
Publication of JP2005501532A5 publication Critical patent/JP2005501532A5/ja
Pending legal-status Critical Current

Links

JP2003506300A 2001-06-01 2002-05-31 キメラフラビウイルスベクター Pending JP2005501532A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29526501P 2001-06-01 2001-06-01
PCT/US2002/017374 WO2002102828A2 (en) 2001-06-01 2002-05-31 Chimeric flavivirus vectors

Publications (2)

Publication Number Publication Date
JP2005501532A JP2005501532A (ja) 2005-01-20
JP2005501532A5 true JP2005501532A5 (https=) 2010-03-25

Family

ID=23136958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003506300A Pending JP2005501532A (ja) 2001-06-01 2002-05-31 キメラフラビウイルスベクター

Country Status (11)

Country Link
US (2) US7569383B2 (https=)
EP (1) EP1401859B1 (https=)
JP (1) JP2005501532A (https=)
KR (1) KR100921592B1 (https=)
CN (1) CN1551782A (https=)
AU (1) AU2002322026B2 (https=)
BR (1) BR0210907A (https=)
CA (1) CA2448971C (https=)
ES (1) ES2439724T3 (https=)
PL (1) PL371187A1 (https=)
WO (1) WO2002102828A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
WO2002102828A2 (en) * 2001-06-01 2002-12-27 Acambis, Inc. Chimeric flavivirus vectors
US20050002968A1 (en) * 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
KR101194818B1 (ko) * 2002-01-15 2012-10-25 사노피 파스테르 바이오로직스, 엘엘씨 플라비바이러스 백신
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
ATE452900T1 (de) * 2002-11-15 2010-01-15 Sanofi Pasteur Biologics Co Impfstoff gegen das west-nile-virus
RU2009105099A (ru) * 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) Конструирование рекомбинантных вирусных вакцин путем прямой транспозон-опосредованной инсерции чужеродных иммунологических детерминант в белки векторного вируса
KR20090096414A (ko) * 2006-09-29 2009-09-10 사노피 파스테르 바이오로직스 씨오 재조합 리노바이러스 벡터
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
CL2007003209A1 (es) 2006-11-07 2008-05-09 Acambis Inc Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion
CA2676775A1 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
AU2009223727B2 (en) 2008-03-14 2014-09-11 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
MX2010010457A (es) * 2008-03-27 2010-11-05 Sanofi Pasteur Biologics Co Vectores recombinantes de rinovirus.
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
EP2408477A4 (en) * 2009-03-16 2013-03-27 Sanofi Pasteur Biologics Llc REPLICATION DEFECTS FLAVIVIRUS VACCINE VACCINATORS AGAINST RESPIRATORY SYNZYTIAL VIRUS
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
EP2771366A4 (en) * 2011-10-25 2015-06-03 Florida Gulf Coast University Board Of Trustees VACCINES AND METHOD FOR PRODUCING A VACCINE FOR INDUCING IMMUNITY AGAINST ALL SERGENT TYPES OF THE DENGUE VIRUS
KR20150036593A (ko) * 2012-07-24 2015-04-07 사노피 파스퇴르 뎅기열 바이러스 감염 예방용 백신 조성물
MX381497B (es) 2012-07-24 2025-03-12 Sanofi Pasteur Composiciones vacuna.
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CN103352029A (zh) * 2013-07-29 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 一种乙脑/森林脑炎嵌合病毒及其应用
BR112016029201B8 (pt) 2014-06-20 2023-12-05 Us Health Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
BR112017028212A2 (pt) 2015-07-03 2018-09-11 Sanofi Pasteur vacinação concomitante contra dengue e febre amarela
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
MX2019011599A (es) 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
WO2019040994A1 (en) 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
US20220168412A1 (en) * 2019-04-10 2022-06-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese Encephalitis Virus
CN111798712B (zh) * 2020-07-15 2021-10-29 周晓庆 噬菌体侵染细菌3d智能模拟方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
DE69231570T2 (de) 1991-09-19 2001-06-21 Us Of America Represented By D Chimäre und/oder wachstumgehemmte Flaviviren
US6136561A (en) * 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
HU228705B1 (en) 1997-02-28 2013-05-28 Univ St Louis Chimeric flavivirus vaccines
BRPI9701774B8 (pt) * 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
CA2383100A1 (en) * 1999-08-20 2001-03-01 Wisconsin Alumni Research Foundation Aspartic and malic acid inhibition of .beta.-glucuronidase
WO2001039802A1 (en) 1999-12-01 2001-06-07 Oravax, Inc. Chimeric flavivirus vaccines
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector
WO2002102828A2 (en) 2001-06-01 2002-12-27 Acambis, Inc. Chimeric flavivirus vectors
US6682883B1 (en) * 2001-07-19 2004-01-27 Acambis, Inc. Diagnosis of flavivirus infection
KR20120016315A (ko) 2001-10-19 2012-02-23 사노피 파스테르 바이오로직스 씨오 동물의 플라비바이러스 감염 예방 및 치료 방법
US20050002968A1 (en) 2002-01-15 2005-01-06 Monath Thomas P. Flavivirus vaccines
KR101194818B1 (ko) 2002-01-15 2012-10-25 사노피 파스테르 바이오로직스, 엘엘씨 플라비바이러스 백신
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
ATE452900T1 (de) 2002-11-15 2010-01-15 Sanofi Pasteur Biologics Co Impfstoff gegen das west-nile-virus
US7189403B2 (en) * 2003-06-30 2007-03-13 Institut Pasteur Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
WO2005040390A1 (en) 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
WO2005049815A1 (en) 2003-11-21 2005-06-02 K.U.Leuven Research & Development Flavivirus replication
JP4993301B2 (ja) 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.

Similar Documents

Publication Publication Date Title
JP2005501532A5 (https=)
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
EA200401064A1 (ru) Вирусоподобные частицы из вируса папилломы человека
EP2275131A3 (en) HCV Vaccines
JP2004538039A5 (https=)
DK0702085T3 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
EP1741782A9 (en) Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
JP2002524024A5 (https=)
DK1523329T3 (da) Viruspartikeladjuvant
JP2003160581A5 (https=)
EP2290091A3 (en) Recombinant measles viruses expressing epitopes of antigens of RNA viruses and use of the recombinant viruses for the preparation of vaccine compositions
DE60042816D1 (de) T-helferzellen-epitope
EP1399481A4 (en) RECOMBINANT ANTIBODIES TO INFECTIOUS BURSAL DISEASE VIRUS (IBDV)
EP1392842A4 (en) RECOMBINANT VACCINIA VIRUS VECTORS
ATE392903T1 (de) Impfstoff gegen pferdeherpesvirus
CL2010001175A1 (es) Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
JP2005534326A5 (https=)
DK1002092T3 (da) Mimotoper af hypervariabel region 1 af E2-glycoproteinet fra HCV og anvendelser deraf
JP2005517783A5 (https=)
JP2007516701A5 (https=)
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
JP2006022119A5 (https=)
AU2002952524A0 (en) Epstein barr virus peptide epitopes
RU2001127052A (ru) Штамм вируса Эбола "Заир Ч-15" для проведения модельных экспериментов и приготовления диагностических и вакцинных препаратов
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена